Denmark
· Delayed Price · Currency is DKK Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 83.37 billion. The enterprise value is 62.10 billion.
| Market Cap | 83.37B |
| Enterprise Value | 62.10B |
Important Dates
The next estimated earnings date is Thursday, August 7, 2025.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.62 million shares outstanding. The number of shares has decreased by -61.77% in one year.
| Current Share Class | 61.62M |
| Shares Outstanding | 61.62M |
| Shares Change (YoY) | -61.77% |
| Shares Change (QoQ) | +587.81% |
| Owned by Insiders (%) | 1.12% |
| Owned by Institutions (%) | 54.47% |
| Float | 60.93M |
Valuation Ratios
The trailing PE ratio is 10.68 and the forward PE ratio is 13.52. Genmab's PEG ratio is 47.42.
| PE Ratio | 10.68 |
| Forward PE | 13.52 |
| PS Ratio | 3.74 |
| PB Ratio | 2.28 |
| P/TBV Ratio | 3.79 |
| P/FCF Ratio | 10.42 |
| P/OCF Ratio | 10.12 |
| PEG Ratio | 47.42 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.75, with an EV/FCF ratio of 7.76.
| EV / Earnings | 7.90 |
| EV / Sales | 2.78 |
| EV / EBITDA | 7.75 |
| EV / EBIT | 8.20 |
| EV / FCF | 7.76 |
Financial Position
The company has a current ratio of 5.34, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.34 |
| Quick Ratio | 5.32 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.12 |
| Debt / FCF | 0.12 |
| Interest Coverage | 59.70 |
Financial Efficiency
Return on equity (ROE) is 22.80% and return on invested capital (ROIC) is 13.34%.
| Return on Equity (ROE) | 22.80% |
| Return on Assets (ROA) | 11.54% |
| Return on Invested Capital (ROIC) | 13.34% |
| Return on Capital Employed (ROCE) | 18.83% |
| Revenue Per Employee | 8.45M |
| Profits Per Employee | 2.98M |
| Employee Count | 2,682 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 11.54 |
Taxes
In the past 12 months, Genmab has paid 1.26 billion in taxes.
| Income Tax | 1.26B |
| Effective Tax Rate | 13.85% |
Stock Price Statistics
The stock price has decreased by -25.08% in the last 52 weeks. The beta is 0.82, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -25.08% |
| 50-Day Moving Average | 1,356.56 |
| 200-Day Moving Average | 1,496.30 |
| Relative Strength Index (RSI) | 41.20 |
| Average Volume (20 Days) | 151,887 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 22.30 billion and earned 7.86 billion in profits. Earnings per share was 126.72.
| Revenue | 22.30B |
| Gross Profit | 21.21B |
| Operating Income | 7.58B |
| Pretax Income | 9.13B |
| Net Income | 7.86B |
| EBITDA | 7.90B |
| EBIT | 7.58B |
| Earnings Per Share (EPS) | 126.72 |
Balance Sheet
The company has 22.27 billion in cash and 986.95 million in debt, giving a net cash position of 21.28 billion or 345.31 per share.
| Cash & Cash Equivalents | 22.27B |
| Total Debt | 986.95M |
| Net Cash | 21.28B |
| Net Cash Per Share | 345.31 |
| Equity (Book Value) | 36.55B |
| Book Value Per Share | 577.05 |
| Working Capital | 22.64B |
Cash Flow
In the last 12 months, operating cash flow was 8.24 billion and capital expenditures -242.21 million, giving a free cash flow of 8.00 billion.
| Operating Cash Flow | 8.24B |
| Capital Expenditures | -242.21M |
| Free Cash Flow | 8.00B |
| FCF Per Share | 129.79 |
Margins
Gross margin is 95.12%, with operating and profit margins of 33.97% and 35.27%.
| Gross Margin | 95.12% |
| Operating Margin | 33.97% |
| Pretax Margin | 40.94% |
| Profit Margin | 35.27% |
| EBITDA Margin | 35.43% |
| EBIT Margin | 33.97% |
| FCF Margin | 35.87% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 61.77% |
| Shareholder Yield | n/a |
| Earnings Yield | 9.43% |
| FCF Yield | 9.59% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 9.65 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.65 |
| Piotroski F-Score | 5 |